JP2012515893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515893A5 JP2012515893A5 JP2011545757A JP2011545757A JP2012515893A5 JP 2012515893 A5 JP2012515893 A5 JP 2012515893A5 JP 2011545757 A JP2011545757 A JP 2011545757A JP 2011545757 A JP2011545757 A JP 2011545757A JP 2012515893 A5 JP2012515893 A5 JP 2012515893A5
- Authority
- JP
- Japan
- Prior art keywords
- sicam
- patient
- vector
- immunogenic composition
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000013598 vector Substances 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000004797 therapeutic response Effects 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305044.1 | 2009-01-20 | ||
| EP09305044 | 2009-01-20 | ||
| EP09305294.2 | 2009-04-07 | ||
| EP09305294 | 2009-04-07 | ||
| PCT/EP2010/050532 WO2010084100A1 (en) | 2009-01-20 | 2010-01-18 | Soluble icam-1 as biomarker for prediction of therapeutic response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515893A JP2012515893A (ja) | 2012-07-12 |
| JP2012515893A5 true JP2012515893A5 (cg-RX-API-DMAC7.html) | 2013-01-17 |
| JP5379243B2 JP5379243B2 (ja) | 2013-12-25 |
Family
ID=42028081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545757A Expired - Fee Related JP5379243B2 (ja) | 2009-01-20 | 2010-01-18 | 患者を選択するためのバイオマーカーおよびそれに関連する方法 |
Country Status (23)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103175959B (zh) * | 2013-02-28 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破免疫层析试纸的制备方法 |
| CN103235134B (zh) * | 2013-05-08 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破的免疫层析试纸及其制备方法 |
| CN103698537A (zh) * | 2014-01-06 | 2014-04-02 | 天津医科大学总医院 | 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法 |
| AU2019231300A1 (en) | 2018-03-06 | 2020-10-08 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2602790B1 (fr) * | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
| ES2080044T3 (es) | 1987-05-04 | 1996-02-01 | Dana Farber Cancer Inst Inc | Moleculas de adhesion intercelular y sus ligandos de fijacion. |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| CA2008368C (en) | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| ES2220448T3 (es) | 1999-02-04 | 2004-12-16 | Geron Corporation | Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa. |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| PT1335987E (pt) | 2000-11-23 | 2006-05-31 | Bavarian Nordic As | Variante do virus vacina modificado ancara |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| PT2241325E (pt) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| US7381536B2 (en) | 2005-03-01 | 2008-06-03 | Gurbel Paul A | Assessment of cardiac health and thrombotic risk in a patient |
-
2010
- 2010-01-18 PT PT107041154T patent/PT2382474E/pt unknown
- 2010-01-18 BR BRPI1006901A patent/BRPI1006901A2/pt not_active Application Discontinuation
- 2010-01-18 HR HRP20150470TT patent/HRP20150470T1/hr unknown
- 2010-01-18 CN CN201080004940.8A patent/CN102292638B/zh not_active Expired - Fee Related
- 2010-01-18 SG SG2014004030A patent/SG196837A1/en unknown
- 2010-01-18 CA CA2749192A patent/CA2749192A1/en not_active Abandoned
- 2010-01-18 KR KR1020117016841A patent/KR20110116016A/ko not_active Abandoned
- 2010-01-18 US US13/145,336 patent/US20110312525A1/en not_active Abandoned
- 2010-01-18 HU HUE10704115A patent/HUE025015T2/en unknown
- 2010-01-18 JP JP2011545757A patent/JP5379243B2/ja not_active Expired - Fee Related
- 2010-01-18 AU AU2010206195A patent/AU2010206195B2/en not_active Ceased
- 2010-01-18 PL PL10704115T patent/PL2382474T3/pl unknown
- 2010-01-18 NZ NZ593749A patent/NZ593749A/xx not_active IP Right Cessation
- 2010-01-18 ES ES10704115.4T patent/ES2536747T3/es active Active
- 2010-01-18 SG SG2011052404A patent/SG173065A1/en unknown
- 2010-01-18 MX MX2011007386A patent/MX2011007386A/es active IP Right Grant
- 2010-01-18 WO PCT/EP2010/050532 patent/WO2010084100A1/en not_active Ceased
- 2010-01-18 EP EP10704115.4A patent/EP2382474B1/en not_active Not-in-force
- 2010-01-18 DK DK10704115T patent/DK2382474T3/en active
- 2010-01-20 TW TW099101520A patent/TWI440854B/zh not_active IP Right Cessation
-
2011
- 2011-05-24 IL IL213098A patent/IL213098A/en not_active IP Right Cessation
- 2011-07-18 ZA ZA2011/05271A patent/ZA201105271B/en unknown
- 2011-07-19 CO CO11090083A patent/CO6390020A2/es not_active Application Discontinuation
- 2011-08-17 CR CR20110438A patent/CR20110438A/es not_active Application Discontinuation
-
2013
- 2013-05-23 US US13/900,869 patent/US20140023686A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bergis et al. | High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma | |
| Tsuchiya et al. | Biomarkers for the early diagnosis of hepatocellular carcinoma | |
| Newman et al. | Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases | |
| Xia et al. | Golgi protein 73 and its diagnostic value in liver diseases | |
| Wang et al. | Pulmonary fibrosis: pathogenesis and therapeutic strategies | |
| RU2013106940A (ru) | Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы | |
| Kim et al. | Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma | |
| Li et al. | Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection | |
| RU2014118584A (ru) | Композиции и способы лечения сердечной недостаточности | |
| Chwist et al. | A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study | |
| CN106405104A (zh) | 一种新的肝硬化或肝纤维化标志物 | |
| ITMI20092154A1 (it) | Marcatore biochimico serico | |
| Hwang et al. | Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma | |
| Jaroszewicz et al. | Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment | |
| Hsiao et al. | Proteomic profiling of the cancer cell secretome: informing clinical research | |
| JP2012515893A5 (cg-RX-API-DMAC7.html) | ||
| Pan et al. | Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma | |
| Sagar et al. | The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study | |
| JP2013543117A5 (cg-RX-API-DMAC7.html) | ||
| CA2798181A1 (en) | Combination therapy and method for assessing resistance to treatment | |
| HRP20150470T1 (hr) | Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora | |
| JP2016095233A (ja) | 早期肝細胞がん患者の再発リスクの予測を補助する方法、システム及びコンピュータプログラム製品 | |
| JP2012521549A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine | |
| Liu et al. | Metabolomics and proteomics reveal blocking argininosuccinate synthetase 1 alleviates colitis in mice |